These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 16616932)

  • 1. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
    Frembgen-Kesner T; Elcock AH
    J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein flexibility in ligand docking and virtual screening to protein kinases.
    Cavasotto CN; Abagyan RA
    J Mol Biol; 2004 Mar; 337(1):209-25. PubMed ID: 15001363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and selection of flexible proteins for structure-based drug design: backbone and side chain movements in p38 MAPK.
    Subramanian J; Sharma S; B-Rao C
    ChemMedChem; 2008 Feb; 3(2):336-44. PubMed ID: 18081134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational selection of protein kinase A revealed by flexible-ligand flexible-protein docking.
    Huang Z; Wong CF
    J Comput Chem; 2009 Mar; 30(4):631-44. PubMed ID: 18711718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
    Sotriffer CA; Krämer O; Klebe G
    Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining docking and molecular dynamic simulations in drug design.
    Alonso H; Bliznyuk AA; Gready JE
    Med Res Rev; 2006 Sep; 26(5):531-68. PubMed ID: 16758486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking of balanol to dynamics snapshots of protein kinase A.
    Wong CF; Kua J; Zhang Y; Straatsma TP; McCammon JA
    Proteins; 2005 Dec; 61(4):850-8. PubMed ID: 16245317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDS: flexible ligand and receptor docking with a continuum solvent model and soft-core energy function.
    Taylor RD; Jewsbury PJ; Essex JW
    J Comput Chem; 2003 Oct; 24(13):1637-56. PubMed ID: 12926007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.
    Perola E; Walters WP; Charifson PS
    Proteins; 2004 Aug; 56(2):235-49. PubMed ID: 15211508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel lipid binding site formed by the MAP kinase insert in p38 alpha.
    Diskin R; Engelberg D; Livnah O
    J Mol Biol; 2008 Jan; 375(1):70-9. PubMed ID: 17999933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM; Hayes JM; Tiraidis C; Zographos SE; Leonidas DD; Chrysina ED; Archontis G; Oikonomakos NG; Paul JV; Varghese B; Loganathan D
    Proteins; 2008 May; 71(3):1307-23. PubMed ID: 18041758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads.
    Badrinarayan P; Sastry GN
    J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating receptor flexibility in the molecular design of protein interfaces.
    Li L; Liang S; Pilcher MM; Meroueh SO
    Protein Eng Des Sel; 2009 Sep; 22(9):575-86. PubMed ID: 19643976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
    Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
    J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.